A Study of the Safety, Tolerability, and Pharmacokinetics of NYR-BI03 in Healthy Participants
Status:
COMPLETED
Trial end date:
2025-07-25
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if investigational drug NYR-BI03 is safe and tolerated when given as an intravenous infusion for up to 6 hours to healthy male and female volunteers.
The study will also show what if any medical problems participants have when taking drug NYR-BI03 and it will provide information on blood levels of the drug.
Researchers will compare drug NYR-BI03 to a placebo (a similar substance that contains no drug) to see if NYR-BI03 is safe and tolerated.
Participants will be administered drug NYR-BI03 or a placebo via intravenous infusion for up to 6 hours and be assessed by physical examination and laboratory tests.